Partner Mary Leslie Smith was quoted in the June 4, 2013 edition of the Miami Herald in an article titled, “Advice to graduates: Combine networking with true passions.” The article offered networking and career advice to young professionals, highlighting ways in which to build the right networks, learn the right skills, and lay a foundation to become a successful leader in the future. Ms. Smith noted in the article that it is worth the time investment to build and maintain social networks, but that is only one piece of the puzzle — connecting in person builds shared experiences that strengthen relationships. She also added that building a vibrant network includes forging relationships at all levels. “Ten years from now that associate next door may be a general counsel who becomes a client. The more friendships, the more relationships you build, the better.” Ms. Smith also noted that one of the best time investments a young professional can make is financial education, particularly for those without business degrees. “Learn to read a financial statement, the key terms in the stock market, how to read a prospectus. It will pay off for you.”
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."